Skip to main content

Table 2 The summary meta-analysis results of association between BRCA1 level with objective response rate (ORR), overall survival (OS) and event-free survival (EFS) in platinum- and toxal-based treatment

From: Breast cancer susceptibility gene 1 (BRCA1) predict clinical outcome in platinum- and toxal-based chemotherapy in non-small-cell lung cancer (NSCLC) patients: a system review and meta-analysis

Comparisons

No of studies (patients)

Percentage of low/negative BRCA1(%)

ORR: low/negative vs high/postive (%)

Overall OR/HR (95% CI) fixed and random

Heterogeneity test

P for publication bias

Platinum-based

      

ORR overall

16(1330)

44.4

48.9 vs 38.1

1.70 (1.32, 2.18), 1.80(1.26,2.55)

I2 = 44.7%,P = 0.03

0.15

Method

      

IHC

13(1066)

44.5

50.7 vs 39.0

1.54(1.17,2.00), 1.59(1.07,2.36)

I2 = 44.8%,P = 0.03

0.41

RT-PCR

4(264)

44.3

43.7 vs 25

2.91 (1.55, 3.83), 2.91(1.55,5.47)

I2 = 0.0%, P = 0.52

0.76

Origin

      

East-Asian

14(1133)

45.4

51.0 vs 36.0

1.68(1.30,2.19), 1.79(1.24,2.60)

I2 = 39.9%,P = 0.04

0.10

Caucasian

3(197)

38.6

39.8 vs 33.4

1.79 (0.84, 3.83), 1.77(0.50,6.28)

I2 = 63.6%,P = 0.06

0.90

OS

8(733)

-

-

1.58(1.27,1.97), 1.65(1.19,2.89)

I2 = 48.4%,P = 0.03

0.13

EFS

6(599)

-

-

1.62(1.28,2.05), 1.60(1.07,2.39)

I2 = 54.5%,P = 0.02

0.88

Toxal-based

      

ORR overall

4(376)

41.3

26.0 vs 46.1

0.41(0.26,0.64), 0.41(0.27,0.64)

I2 = 0.0%, P = 0.61

0.84